Stay updated with breaking news from Express Genes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Twist Bioscience reports strong Q2 earnings, with sales up 25% YoY to $75.3M and orders increasing by 45%. Gross margin expands to 41%. Fiscal year guidance was raised, and William Blair sees continued growth momentum. Analysts reaffirm Outperform ratings.
Revenue Surges 32% Year-Over-Year; Gross Margin Guidance Increased
Twist Bioscience reported Q1 2024 earnings, beating revenue guidance and increasing FY24 guidance. Shares are up 7.16%.
– Record revenue of $71.5M in 1QFY24, an increase of 32% over $54.2M in 1QFY23 – – Orders increased to $77.5M in 1QFY24, an increase of 19% over 1QFY23 – — Increased FY 2024 revenue...
In this article, we will take a detailed look at the 15 Stocks That Will Outperform the S&P 500 in 2024. For a quick overview of such stocks, read our article 5 Stocks That Will Outperform the S&P 500 in 2024. All indicators show that the US economy remains resilient and in a much better shape than expected, […]